Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia
Masnoon Saiyed, Joshua Byrnes, Tushar Srivastava, Paul Scuffham, Martin Downes
Topics & Concepts
LenvatinibSorafenibMedicineHepatocellular carcinomaOncologyInternal medicineCost effectivenessClinical trialRisk analysis (engineering)Hepatocellular Carcinoma Treatment and PrognosisEconomic and Financial Impacts of CancerHealth Systems, Economic Evaluations, Quality of Life